Equities Analysts Offer Predictions for InflaRx Q2 Earnings

InflaRx (NASDAQ:IFRX - Free Report) - Investment analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for InflaRx in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.24) for the quarter, down from their prior estimate of ($0.18). The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for InflaRx's Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.87) EPS and FY2026 earnings at ($0.92) EPS.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million.

IFRX has been the subject of a number of other reports. Oppenheimer started coverage on InflaRx in a report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price objective for the company. Guggenheim increased their price target on InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research note on Wednesday, March 26th. Cantor Fitzgerald started coverage on InflaRx in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of InflaRx in a report on Friday, March 21st.

InflaRx Stock Down 1.5%

Shares of IFRX stock traded down $0.03 during trading hours on Monday, hitting $1.75. 79,972 shares of the company's stock traded hands, compared to its average volume of 230,984. The stock has a market cap of $117.75 million, a PE ratio of -1.62 and a beta of 1.57. The stock's 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.83. InflaRx has a 12 month low of $0.82 and a 12 month high of $2.82.

Institutional Trading of InflaRx

A number of institutional investors have recently bought and sold shares of IFRX. Raymond James Financial Inc. acquired a new position in shares of InflaRx in the 4th quarter valued at about $1,576,000. Northern Trust Corp increased its holdings in InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company's stock worth $1,647,000 after purchasing an additional 634,045 shares in the last quarter. 683 Capital Management LLC lifted its stake in InflaRx by 26.8% in the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock valued at $2,678,000 after buying an additional 555,000 shares during the period. DAFNA Capital Management LLC bought a new position in shares of InflaRx during the 1st quarter worth approximately $459,000. Finally, XTX Topco Ltd acquired a new stake in shares of InflaRx during the 1st quarter worth approximately $38,000. Institutional investors own 42.39% of the company's stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.